Work

Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2024-ct226

Authors: Jameel Muzaffar, Kedar Kirtane, Rebecca Redman, Muh-Hwa Yang, Tae Min Kim, Stephen Liu, Ryan Lynch, Julie Brahmer, Patricia LoRusso, Brian Henick, Sung-bae Kim, Yin-Hsun Feng, Michael Chisamore, Paul Kassner, Dirk Brockstedt, Nicole Nasrah, Rakesh Goyal, William Y. Ho, Victoria Villaflor

Institutions: Duke University, Moffitt Cancer Center, University of Louisville, Taipei Veterans General Hospital, Seoul National University Hospital, Georgetown University, University of Washington, Johns Hopkins University, Yale University, Columbia University, Asan Medical Center, Chi Mei Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Rapt Therapeutics (United States), City Of Hope National Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393983019

Cites:

Cited by: 5

Related to: 10